ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Erbitux (cetuximab) by Year
Erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly Erbitux (cetuximab): $627M in FY2024, up 5.2% from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“|| Erbitux | 562.1 | 65.3 | 627.4 | 596.5 | 5”
Source: Form 10-K FY2024 (filed 2025-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 627 | +5.2% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 597 | +5.3% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 567 | +3.3% | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 548 | +2.2% | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 536 | -15.6% | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 635 | +18.5% | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 536 | -2.2% | Form 10-K (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 548 | -6.6% | Form 10-K (filed 2019-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 587 | +21.0% | Form 10-K (filed 2019-02-19) ↗ |
| FY2015 | Dec 31, 2015 | 485 | +29.9% | Form 10-K (filed 2016-02-19) ↗ |
| FY2014 | Dec 31, 2014 | 373 | -0.1% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 374 | -5.9% | Form 10-K (filed 2014-02-19) ↗ |
| FY2012 | Dec 31, 2012 | 397 | -3.0% | Form 10-K (filed 2013-02-21) ↗ |
| FY2011 | Dec 31, 2011 | 409 | +6.0% | Form 10-K (filed 2012-02-24) ↗ |
| FY2010 | Dec 31, 2010 | 386 | -1.2% | Form 10-K (filed 2011-02-22) ↗ |
| FY2009 | Dec 31, 2009 | 391 | +1,229.3% | Form 10-K (filed 2011-02-22) ↗ |
| FY2008 | Dec 31, 2008 | 29.4 | – | Form 10-K (filed 2011-02-22) ↗ |
Breakdown
What makes up erbitux (cetuximab)
Cite this data
StockData. (2026). Eli Lilly Erbitux (cetuximab) ($M), annual FY2008–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-erbitux-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.